Astra Zeneca/Starpharma Combination Potential Blockbuster Anticancer Drug Approved For Clinical Tria, page-4

So let's look at the AstraZeneca collaboration once again

2012 - 6th September
Birth of the evaluation agreement to look at Starpharma's Dendrimer enhanced products in conjunction with the drug delivery technology

2014 - 7th July
Twenty months down the track, the agreement is expanded with a further evaluation to exam drug delivery platform

2015 - 4th May
10 months later - an extension to the existing collaboration comes into play

2015 - 7th September
4 months later - a licensing agreement is signed and deal is ratified with AUD$2.9 million payment to Starpharma. The deal encompasses milestones and royalties to the value of US$450 million for a successful first candidate and subsequent candidates inclusive of milestones and royalties amounting to US$417 million. And further to this - depending on the number of indications per candidate a much higher revenue stream over the life of each indication

2016 - 28th July
Just over 10 months later an additional agreement outside scope of existing license agreement is signed. In this collaboration - Astrazeneca will focus on an as yet undisclosed drug currently in the market place which is coming to the end of it's patent life. Hopefully further announcements in relation to this partnership will be made public very shortly

2017 - 20th April
Nine months later a milestone of final preclinical on the first candidate is reached and a AUD$2.6 million payment is put into Starpharma's bank account. Comments made by Astrazeneca in relation to Starpharma were as I quote the following

"Very exciting novel oncology agent"

"Relationship highly productive"

2017 - 28th September
Five months later, the first candidate utilising Starpharma DEP delivery platform is formally presented publicly as AZD0466.

June - 2019
Starpharma has today announced a Development and Option Agreement with AstraZeneca to progress the development (of a Dendrimer Enhanced Product (DEP) version )of an undisclosed AstraZeneca major marketed oncology medicine.

September - 2019
IND application approved to go into clinical trials..... hopefully between now and end of calendar year 2019

Once this clinical trial begins Starpharma will receive a further milestone payment of US$3 million into it's accounts

As you can see the genesis of collaboration has developed quite nicely over the last several years

We are getting into some serious growth here. The milestones will start to become more frequent as time goes on

One thing to remember is all the development and marketing costs of succesful candidates will be picked up by Astrazeneca. Isn't that amazing - no outlay by Starpharma.

Possibly the next couple of months we will bring forth a plethora of market sensitive announcements
,
That snowball is definitely picking up momentum again